Health Care Innovation
Commentary
Private Efforts Not Public Committees Will Generate Healthcare Savings
Passed as part of the Affordable Care Act (ACA), the Center for Medicare & Medicaid Innovation (CMMI) was allocated $10 billion in 2011 for the first decade of its existence. It has been allocated hundreds of millions more since. The purpose of the program is to create payment models that ...
Drug Importation
Listen to Sally Pipes on “Free the Economy” podcast
Listen to PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes discuss her new book The World’s Medicine Chest (Encounter Books) on the Free the Economy podcast from the Competitive Enterprise Institute. Click here to listen
Blog
Read the latest on the push for drug price controls
To Improve Drug Affordability Congress Should Fix the Payment System
Demanding that drug prices in the U.S. equal overseas prices is akin to demanding that the price of all expensive handbags should equal the prices for the knockoffs that people purchase from street vendors. Of course knockoff bags are cheaper. They violate the intellectual property rights of the bag’s maker, ...
Commentary
President Trump Hasn’t Given Up on Hospital Price Transparency
For markets to function efficiently, consumers need to know how much things cost. This is as true for eggs and milk as it is for medical care. And it was this very insight that motivated the rule that President Donald J. Trump implemented during his first term in 2019 ordering ...
Commentary
Is Era of Biomedical Innovation Wins Against Cancer Over?
For evidence of the astounding progress made by medical science in recent decades, look no further than the Annual Report to the Nation on the Status of Cancer, which was jointly issued by the American Cancer Society, the Centers for Disease Control and Prevention, the North American Association of Central ...
Commentary
Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Drug Importation
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Commentary
Why Are Republicans Acquiescing To Tax Hikes?
The White House is advancing a policy that would raise drug prices, stifle medical innovation, and hand China a strategic edge in the race for global technological dominance. No, Joe Biden hasn’t somehow returned to office. This time, the ill-advised idea — tariffs on imported medicines — comes from Donald ...
Commentary
Banning mRNA vaccines would stop emerging cancer treatments
Several states have effectively declared war on medical progress. Lawmakers in Iowa, Montana, Idaho, Texas and Kentucky introduced bills that would ban or restrict vaccines that use messenger RNA, or mRNA, technology — despite its immense potential for treating and even preventing some of the most vexing diseases known to ...
Commentary
Deregulation Is The Pathway To Greater Pharmaceutical Innovation
Surveys confirm that most Americans recognize the value of prescription drugs. But the same surveys also show that Americans are worried that they will be unable to afford needed medicines. These conflicting feelings exemplify the inherent tension when it comes to prescription drugs – how do we incentivize innovation to ...
Private Efforts Not Public Committees Will Generate Healthcare Savings
Passed as part of the Affordable Care Act (ACA), the Center for Medicare & Medicaid Innovation (CMMI) was allocated $10 billion in 2011 for the first decade of its existence. It has been allocated hundreds of millions more since. The purpose of the program is to create payment models that ...
Listen to Sally Pipes on “Free the Economy” podcast
Listen to PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally C. Pipes discuss her new book The World’s Medicine Chest (Encounter Books) on the Free the Economy podcast from the Competitive Enterprise Institute. Click here to listen
Read the latest on the push for drug price controls
To Improve Drug Affordability Congress Should Fix the Payment System
Demanding that drug prices in the U.S. equal overseas prices is akin to demanding that the price of all expensive handbags should equal the prices for the knockoffs that people purchase from street vendors. Of course knockoff bags are cheaper. They violate the intellectual property rights of the bag’s maker, ...
President Trump Hasn’t Given Up on Hospital Price Transparency
For markets to function efficiently, consumers need to know how much things cost. This is as true for eggs and milk as it is for medical care. And it was this very insight that motivated the rule that President Donald J. Trump implemented during his first term in 2019 ordering ...
Is Era of Biomedical Innovation Wins Against Cancer Over?
For evidence of the astounding progress made by medical science in recent decades, look no further than the Annual Report to the Nation on the Status of Cancer, which was jointly issued by the American Cancer Society, the Centers for Disease Control and Prevention, the North American Association of Central ...
Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies ...
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Why Are Republicans Acquiescing To Tax Hikes?
The White House is advancing a policy that would raise drug prices, stifle medical innovation, and hand China a strategic edge in the race for global technological dominance. No, Joe Biden hasn’t somehow returned to office. This time, the ill-advised idea — tariffs on imported medicines — comes from Donald ...
Banning mRNA vaccines would stop emerging cancer treatments
Several states have effectively declared war on medical progress. Lawmakers in Iowa, Montana, Idaho, Texas and Kentucky introduced bills that would ban or restrict vaccines that use messenger RNA, or mRNA, technology — despite its immense potential for treating and even preventing some of the most vexing diseases known to ...
Deregulation Is The Pathway To Greater Pharmaceutical Innovation
Surveys confirm that most Americans recognize the value of prescription drugs. But the same surveys also show that Americans are worried that they will be unable to afford needed medicines. These conflicting feelings exemplify the inherent tension when it comes to prescription drugs – how do we incentivize innovation to ...
